Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation and Depletion: 2022-2024

Historic Depreciation and Depletion for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Sep 2024 value amounting to $76,000.

  • Orchestra BioMed Holdings' Depreciation and Depletion rose 7.04% to $76,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $296,000, marking a year-over-year increase of 4.23%. This contributed to the annual value of $287,000 for FY2023, which is 29.28% up from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Depreciation and Depletion stood at $76,000 for Q3 2024, which was up 2.70% from $74,000 recorded in Q2 2024.
  • Orchestra BioMed Holdings' 5-year Depreciation and Depletion high stood at $76,000 for Q3 2024, and its period low was $48,000 during Q1 2022.
  • Moreover, its 3-year median value for Depreciation and Depletion was $71,000 (2023), whereas its average is $66,455.
  • Data for Orchestra BioMed Holdings' Depreciation and Depletion shows a peak YoY soared of 47.92% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Orchestra BioMed Holdings' Depreciation and Depletion stood at $70,000 in 2022, then increased by 2.86% to $72,000 in 2023, then climbed by 7.04% to $76,000 in 2024.
  • Its Depreciation and Depletion was $76,000 in Q3 2024, compared to $74,000 in Q2 2024 and $74,000 in Q1 2024.